Related references
Note: Only part of the references are listed.Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells
Michael Lidsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Towards a Unified Model of RAF Inhibitor Resistance
David B. Solit et al.
CANCER DISCOVERY (2014)
An open investigation of the reproducibility of cancer biology research
Timothy M. Errington et al.
ELIFE (2014)
ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
A. P. Rebocho et al.
ONCOGENE (2013)
Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs
Daniel Lakens
FRONTIERS IN PSYCHOLOGY (2013)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
Leisl M. Packer et al.
CANCER CELL (2011)
Mechanisms of Resistance to RAF Inhibitors in Melanoma
Andrew E. Aplin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
F. M. Kaplan et al.
ONCOGENE (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
Josette Carnahan et al.
MOLECULAR CANCER THERAPEUTICS (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
John T. Lee et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences
Franz Faul et al.
BEHAVIOR RESEARCH METHODS (2007)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
Nicolas Dumaz et al.
CANCER RESEARCH (2006)
Share Paper
